Table 2.
Univariate analysis for RFS and DMFS in ER+ breast cancer
| Factors | RFS
|
DMFS
|
||||
|---|---|---|---|---|---|---|
| HR | 95% CI of HR | P-value | HR | 95% CI of HR | P-value | |
| Radiation therapy | 1.624 | 1.030–2.562 | 0.037 | 2.384 | 1.301–4.371 | 0.005 |
| Histologic grade | 2.480 | 1.568–3.922 | 0.000 | 2.856 | 1.553–5.250 | 0.001 |
| Ki-67 | 1.873 | 1.170–2.996 | 0.009 | 1.987 | 1.046–3.775 | 0.036 |
| Node status | 0.004 | 0.003 | ||||
| 1–3 vs 0 | 1.474 | 0.853–2.548 | 0.164 | 2.088 | 1.004–4.343 | 0.049 |
| >3 vs 0 | 2.524 | 1.461–4.362 | 0.001 | 3.535 | 1.700–7.351 | 0.001 |
| TNM | 0.028 | 0.014 | ||||
| II vs I | 1.073 | 0.631–1.826 | 0.794 | 1.329 | 0.622–2.839 | 0.463 |
| III vs I | 2.062 | 1.154–3.683 | 0.015 | 2.999 | 1.361–6.607 | 0.006 |
| Age | 1.032 | 0.654–1.627 | 0.892 | 0.909 | 0.495–1.669 | 0.757 |
| Menopausal status | 1.203 | 0.754–1.918 | 0.438 | 0.914 | 0.496–1.685 | 0.773 |
| Tumor size | 1.066 | 0.680–1.671 | 0.781 | 1.369 | 0.746–2.514 | 0.311 |
| Pathologic type | 0.960 | 0.667–1.382 | 0.825 | 0.667 | 0.350–1.270 | 0.218 |
| HER2 | 0.974 | 0.579–1.639 | 0.922 | 1.201 | 0.613–2.351 | 0.594 |
| Chemotherapy | 1.123 | 0.560–2.253 | 0.743 | 1.083 | 0.425–2.755 | 0.868 |
| Endocrine therapy | 1.188 | 0.693–2.038 | 0.531 | 0.646 | 0.272–1.533 | 0.322 |
| PR | 0.842 | 0.471–1.504 | 0.561 | 0.807 | 0.374–1.745 | 0.587 |
Note: Bold values show statistical significance (P<0.05).
Abbreviations: DMFS, distant metastasis-free survival; ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor; RFS, recurrence-free survival.